Stage-specific differentiation markers were used to evaluate the cellular composition and the origin of nonimmortalized (PrEC) and immortalized (PZ-HPV7, CA-HPV10, RWPE-1, and 957E/hTERT) human prostate cell lines. These studies documented that immortalized and nonimmortalized prostate epithelial cells established and maintained in low (i.e., <300 Mmol/L) Ca 2+ serum-free defined (SFD) medium were all derived from normal nonmalignant prostate tissues and contain CD133
Introduction
The normal human prostate is composed of a stratified epithelium that is functionally organized in stem cell units (refs. 1-11; Fig. 1) . Recently, the nature of prostate stem cells has become a subject of intense investigation. In particular, Hudson et al. showed that f0.5% of epithelial cells isolated from normal human prostate tissue attach rapidly to type I collagen-coated dishes and possess the highest clonogenic ability of any prostatic cell subtype when grown in low (i.e., <300 Amol/L) Ca 2+ serum-free defined (SFD) medium (4) . In an effort to further characterize these putative stem cells, the authors documented that they are derived from the basal layer of prostatic epithelium (4) . Collins et al. showed that such rapid attachment is due to high expression of a 2 h 1 integrins by these putative stem cells (6) . Richardson et al. further showed that when cells are directly isolated from prostate tissue and passaged in low (i.e., <100 Amol/L) Ca 2+ SFD medium, CD133 + / a 2 h 1 Hi -coexpressing putative stem cells in these cultures have the highest clonogenic ability and the longest proliferative life span in comparison with CD133 À cells (10) . Huss et al. reported that prostatic stem cells also express the ABC transporter G2 isotype (i.e., ABCG2) protein but not androgen receptor (AR) or p63 proteins (11) . The p63 À /AR À status of prostate stem cells is consistent with the observations that embryonic epithelial cells from the urogenital sinus of either AR or p63 knockout mice still undergo prostatic organogenesis and glandular renewal when transplanted in combination with wild-type urogenital sinus mesenchyme into the kidney of nude mice (12) (13) (14) . In summary, the prostate stem cells can be identified based on their unique molecular CD133 + /ABCG2 + /a 2 h 1 Hi /p63 À /PSCA À /AR À /PSA À expression profile (Fig. 1 ).
Although prostate stem cells possess high self-renewal capacity, they proliferate infrequently to renew themselves and simultaneously generate progeny for two distinct prostate epithelial cell lineages. The first and much less frequent lineage commitment is differentiation into proliferatively quiescent neuroendocrine cells (7, 13) . The second and much more common lineage commitment involves differentiation into transit-amplifying cells that undergo a limited number of divisions (i.e., amplifications) before transiting a maturation process of terminal differentiation (refs. 1, 9; Fig. 1 ). These transit-amplifying cells do not express AR protein and are dependent for proliferation but not survival on AR signaling in the stroma (9, 15) . In contrast to stem cells, transit-amplifying cells obligatorily express the basal epithelial marker p63 (16, 17) as well as other basal markers, such as cytokeratins 5 and 14 (3, 5, 16, 17) , Jagged-1, and Notch-1 (17, 18) . Transit-amplifying cells express very low levels of luminal cytokeratins 8 and 18 (3, 5, 6, 19) and stain negative for prostate luminal-secretory cell markers, such as NKX3.1, AR, prostate-specific antigen (PSA), or hK2 (15) (16) (17) (18) (19) (Fig. 1) .
After a limited number of divisions (i.e., amplifications), transitamplifying precursors mature into intermediate cells with the concomitant down-regulation of p63, Jagged-1, Notch-1, and basal cytokeratins 5 and 14 (3, 16, 17, 19 Fig. 1 ). 4 Luminalsecretory cells constitute the terminal maturation stage of hierarchically expanding transit-amplifying cells and thus form quantitatively the major epithelial cell type in the gland, although they are proliferatively quiescent (22) . Unlike their proliferating precursors, luminal-secretory cells depend on stromally derived andromedins for survival; hence, androgen ablation or specific inactivation of AR function in prostate stroma induces apoptosis of these cells (1, 9, 23) .
To efficiently study prostatic epithelial differentiation and carcinogenesis, well-characterized in vitro human cell line models are needed. Indeed, nonimmortalized early-passage normal human prostatic epithelial cells, termed PrEC, can be purchased from Cambrex BioSciences (East Rutherford, NJ). In addition, Weijerman et al. (24) and Bello et al. (25) used the human papillomavirus (HPV) 18 DNA to immortalize human prostate epithelial cells from normal prostate to establish the serially passagable PZ-HPV7 and RWPE-1 cell lines, respectively, whereas Weijerman et al., using the same technique, also immortalized prostate epithelia from human prostate cancer tissue establishing the permanent CA-HPV10 cell line. In addition, Yasunaga et al. immortalized the 957E/hTERT cell line via retroviral transduction of a human telomerase (hTERT) subunit into epithelial cells from a patient with hereditary prostate cancer (26) . In determining the cellular origin of these lines, it is important to consider that all of the above nonimmortalized and immortalized lines were established in low (i.e., <300 Amol/L) Ca 2+ SFD medium minimally containing bovine pituitary extract and epidermal growth factor. Such low Ca 2+ SFD medium selects against prostate cancer cells while allowing basal layer-derived normal epithelial cells to grow out (18) . This observation is consistent with why none of the aforementioned normal or cancerderived lines are tumorigenic when inoculated in nude mice (18, (24) (25) (26) .
In present studies, the expression of stage-specific differentiation markers ( Fig. 1) as well as morphologic and growth characteristics was evaluated in the nonimmortalized PrEC and immortalized RWPE-1, PZ-HPV7, CA-HPV10, and 957E/hTERT lines to define their cellular composition and to resolve whether these cultures contain prostate epithelial stem cells. Resolving these issues is important to clarify how each of these lines can be used appropriately for the in vitro studies of both normal prostatic epithelial differentiation and prostatic carcinogenesis.
Materials and Methods
Materials. The synthetic androgen R1881 was purchased from PerkinElmer (Boston, MA). Universal type I IFN was obtained from PBL Biomedical Laboratories (Piscataway, NJ). DU145, LNCaP, PC3, and CA-HPV10 human prostate cancer lines, PZ-HPV7 and RWPE-1 immortalized prostate nonmalignant lines, and SV40-immortalized WPMY-1 prostate stromal cells (27) were purchased from the American Type Culture Collection (Rockville, MD). CWR22Rv1 line (28) was generously provided by Dr. J.W. Jacoberger (Case Western Reserve University, Cleveland, OH). The 957E/hTERT, C4-2B, LAPC-4, and MDA-PC-2B lines were obtained as described previously (18) . The DuCaP (29) (18) . All cells were grown in 5% CO 2 , 95% air humidified incubator at 37jC.
In vitro growth assays. Cell growth was measured by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay from Promega Corp. (Madison WI) as described previously (15, 18) .
Real-time Taqman reverse transcription-PCR quantitation of AR and PSA expression. The Taqman primers and probes for human AR and human kallikrein-3 (i.e., PSA) genes were purchased from Applied Biosystems (Foster City, CA). Total RNA was extracted with Qiagen RNeasy Mini kit (Valencia, CA) according to the manufacturer's instructions. The reverse transcription was carried out using appropriate Taqman reagents and 5 AL of this reaction mixture were used for the subsequent polymerase reaction. The Taqman reverse transcription was carried out on a Bio-Rad ICycler (Hercules, CA). Each reverse transcription-PCR experiment included a standard curve of known copy number using full-length wild-type cDNA of either AR or PSA subcloned into the TA cloning vector (Invitrogen Life Technologies). AR and PSA mRNA levels were determined and expressed as copy number per microgram of total RNA for each cell line.
Western blotting. Western blots were carried out on cell lysates equivalent to 10 5 cells per lane as described previously (15, 18) . Rabbit polyclonal AR, PSCA, and GATA-2 and mouse monoclonal DNp63 isoform antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The rabbit polyclonal TAp63 isoform antibody was purchased from BioLigand (San Diego, CA), whereas rabbit polyclonal Hey-1 and Notch-1 antibodies were purchased from Chemicon International (Temecula, CA) and Cell Signaling (Beverly, MA) respectively. Mouse monoclonal h-actin antibody was purchased from Sigma (St. Louis, MO).
Immunocytochemistry for AR, p63, PSCA, and chromogranin A. Immunocytochemistry was done as described previously (18) using the antibodies described for Western blotting as well as mouse monoclonal chromogranin A antibody (Calbiochem, La Jolla, CA).
Measurement of PSA production. Total PSA in the culture medium was analyzed using the Hybritech ELISA assay on the Beckman Access Immunoassay System (Beckman Coulter, Inc., Brea, CA) as described previously (27) . This assay has a limit of detection of 0.1 ng PSA/mL medium.
Flow cytometry and time-lapse microscopy. One million cells were suspended in wash buffer [PBS, 0.5% bovine serum albumin (BSA), 2 mmol/L EDTA] and antibody incubation was conducted for 10 minutes on ice. Subsequently, the cells were washed and analyzed by a LSR flow cytometer using CellQuest Software (BD Biosciences, Franklin Lakes, NJ). Counts (10 5 ) were obtained in three independent experiments and the percentage of positive cells was determined by comparison with isotype control antibody staining results. Cells were labeled using one or more of the following antibodies: mouse-monoclonal phycoerythrin (PE)-conjugated CD133 antibody (Miltenyi Biotech, Auburn, CA), mouse monoclonal FITC-conjugated ABCG2 antibody (Chemicon), mouse monoclonal PE/Cy5-conjugated h 1 integrin (BioLigand), or a rabbit-polyclonal PSCA (Santa Cruz Biotechnology) followed by a goat anti-rabbit IgG FITC (Santa Cruz Biotechnology). Multichannel analyses for h 1 integrin, CD133, and ABCG2 triple-positive cells were conducted by gating the h 1 integrin and ABCG2 + cells for the expression of CD133. Time-lapse microscopy was done on a TE-2000 Nikon (Melville, NY) microscope with a 37jC heated stage in a 5% CO 2 chamber (Live Cell NEVE Product Group). Images were captured every 20 minutes using a Cool Snap ES CCD camera (Princeton Instruments, Trenton, NJ).
Isolation of CD133 + cells. CD133 + cells were isolated by fluorescenceactivated cell sorting (FACS) using FACS area flow cytometer. Specifically, 3 Â 10 6 PrEC cells were incubated with PE-conjugated CD133 mouse monoclonal antibody and then sorted. Alternatively, CD133 + cells were isolated using magnetic cell isolation per the manufacturer's instructions (Miltenyi Biotech). Briefly, 1 million PrEC cells were labeled with CD133 microbeads, incubated on ice for 30 minutes, and washed with provided buffer (PBS, 0.5% BSA, 2 mmol/L EDTA). Cells were isolated by passage through a series of two magnetic columns and washed and the CD133 + cells were cytospun onto slides for staining or grown in culture.
Results
Nonimmortalized PrEC cultures contain stem cells that undergo limited differentiation in vitro. PrEC cultures obtained commercially are supplied at passage 2 and, although not immortalized, can be serially propagated for up to 10 passages before becoming proliferatively quiescent (15) (16) (17) . These cultures are established and maintained in low (i.e., <300 Amol/L) Ca 2+ SFD medium (18 (13, 14) . To do this, CD133 + cells were isolated by FACS from exponentially growing PrEC cultures. These isolated cells when analyzed immunocytochemically were >80% negative for p63 expression and consistently small. Furthermore, the above immunocytochemical staining revealed the presence of an occasional cell in mitotic telophase in which one of the daughter cells is p63 -, whereas the other daughter cell expresses nuclear p63 ( Fig. 2A) . These results are consistent with one of the daughter cells remaining a CD133 + / p63 À stem cell (arrow) with the other daughter becoming a CD133 À /p63 + transit-amplifying cell. The p63 gene is a definitive marker for prostate transitamplifying cells (33) . The p63 gene can undergo alternative splicing to generate a series of molecular weight variants, including the a, h, and g isoforms, of the TA or DN families of p63 (ref. 34 ; Fig. 2B ). When the entire PrEC culture is subjected to p63 expression analysis by Western blot, all three of the DNp63 isoforms are detected, with the 66-kDa a isoform being the most prominent one (Fig. 2C) . However, these cultures do not express detectable levels of any TAp63 isoforms (Fig. 2C) . At passage <6, the vast majority (i.e., >90%) of PrEC cells are small in size and express nuclear DNp63 protein as detected by immunocytochemistry (Fig. 3A) Fig. S2A ). Eventually, however, after several rounds of division, a subset of progeny becomes highly motile and acquires the ability to migrate apart before undergoing cell proliferation (Supplementary Fig. S2B ). As these colonies expand in low Ca 2+ SFD medium, <10% of small cells undergo maturation into large nonproliferative intermediate cells, whereas f1% to 3% of these cells mature into elongated/ neuroendocrine-type cells ( Supplementary Fig. S2C and D) . Flow cytometric analysis documented that although the large intermediate cells are proliferatively quiescent, the level of PSCA expression per cell, the percentage of PSCA + cells, and the cell size of PSCA + cells increase over time in cultures but never exceed 15% to 20% even when the cultures are maintained for >10 days as shown in Fig. 3D (Fig. 2D) or PSA protein expression was detectable by Western blot (Fig. 5D ) and ELISA assay, respectively, even when the cultures were allowed to age for >2 weeks. medium. This is particularly critical because in establishing permanent lines from malignant tissues, it is often assumed that the outgrowing population will be of malignant phenotype. Indeed, both the CA-HPV10 and 957E/hTERT cell lines were initially established in culture from such malignant tissues using low (i.e., <100 Amol/L) Ca 2+ SFD medium and the cultured cells subsequently were immortalized to produce permanent ''prostate cancer cell lines'' (24, 26) . Likewise, both RWPE-1 and PZ-HPV7 cells were established and immortalized using this low (i.e., <100 Amol/L) Ca 2+ SFD medium but from supposedly normal prostate tissues (24, 25) . However, because prostate cancers are often multifocal and diffuse, the nonmalignant nature of these latter two immortalized lines requires verification and vice versa.
The expression of DNp63a protein can be used to verify malignant versus nonmalignant nature of the immortalized cell lines because this protein is not expressed by prostate cancer cells (33) . As shown earlier, normal nonimmortalized transit-amplifying cells within PrEC cultures express DNp63 isoforms (Fig. 2C and D) . Similarly, the RWPE-1, PZ-HPV7, CA-HPV10, and 957E/hTERT immortalized lines all express detectable levels of DNp63 isoforms (Fig. 2D) . In contrast, none of a series of 11 human prostatic cancer lines (PC3, DU145, LNCaP, C4-2B, MDA-PC-2B, LAPC-4, E006AA, DuCaP, VCaP, CWR22Rv1, and CWR22R1) express any of the DNp63 isoforms and only the LNCaP line and its derivative (C4-2B) express a detectable level of the TAp63g isoform (Fig. 2C) Supplementary Fig. S1C ). In particular, PZ-HPV7 line had the highest (i.e., 1.75 F 0.13%), whereas 957E/hTERT line had the lowest (0.10 F 0.01%) percentage of triple-positive cells. Furthermore, all studied cultures were documented to contain neuroendocrine cells (Fig. 4D) , which is indicative of the presence of stem cells. Further molecular evaluation of these cultures documented that PZ-HPV7 cultures were heterogeneous with respect to cellular composition consisting of small p63 + transit-amplifying and p63 (Fig. 4A-C) . Western blot evaluation of p63, PSCA, and AR expression supports the above immunocytochemistry findings. As documented in Fig. 2D (Fig. 5A) . In contrast, both the CWR22Rv1 human prostate cancer cells and the WPMY-1 immortalized human prostate stroma cells up-regulated AR protein in response to R1881 (Fig. 5A) . Furthermore, R1881 treatment did not simulate the growth of RWPE-1, PZ-HPV7, CA-HPV10, and 957E/hTERT cells (Fig. 5B) . In contrast, a significant growth response was observed in androgen-sensitive, AR + CWR22Rv1 human prostate cancer line but not in the AR + WPMY-1 human prostate stromal line (Fig. 5B) . The latter lack of response is consistent with the previous demonstration that the growth of normal human prostate stromal cells was not stimulated by androgens (35) .
It has been recently reported that the addition of IFN to low Ca 2+ SFD medium induces PrEC cells to increase their level of AR protein expression (36) . To confirm this, RWPE-1 cells were exposed for 24 hours to 1,000 units/mL universal type I IFN in the presence or absence of added androgen (i.e., 1 nmol/L R1881) and AR protein levels were determined by Western blot (Fig. 5C ). These results documented that RWPE-1 cells are able to up-regulate their expression of AR protein; however, the absolute level of expression was still >10-fold lower than that of normal human prostate stromal cells (i.e., WPMY-1 cells; Fig. 5C ), which in turn express 10 2 lower levels of AR protein then prostate cancer cells (e.g., CWR22Rv1; Fig. 5A ). When medium from R1881-and IFN-treated RWPE-1 cells was screened for PSA protein by ELISA assay, no expression was detected. These results document that the addition of IFN to low Ca 2+ SFD culture medium allows intermediate cells to enhance their expression of AR protein but does not induce full differentiation of these cells toward the PSA + luminal-secretory phenotype. Notably, these findings are consistent with previous reports of RWPE-1 cells being able to undergo limited differentiation and acinar formation in three-dimensional Matrigel cultures in the presence of added androgen (37, 38) . Such ability of RWPE-1 cells to undergo acinar differentiation is further suggestive of the presence of prostate stem cells in these cultures.
Effect of Notch-1 signaling on differentiation of intermediate cells into luminal-secretory cells. We have documented previously that in PrEC cells grown in low Ca 2+ SFD medium Notch signaling is constitutively active even in the absence of cell contact (i.e., receptor-ligand interaction; ref. 18 ). This phenomenon is explained by the ability of g secretase in such low Ca 2+ medium to proteolytically process Notch-1 receptor, thereby producing the active 110-kDa cleaved Notch transcription factor (18) . Hey-1 is a direct transcriptional target of this cleaved Notch fragment and Research. (39) . The Hey-1 gene encodes a basic helix-loop-helix protein, which forms a Hey-1/NCoR/Sin3/HDAC1 repressor complex and downregulates the expression of a series of genes, including the family of GATA transcription factors (39, 40) . Furthermore, in addition to repressing GATA-2 and GATA-3 expression transcriptionally, Hey-1 also physically complexes with GATA transcription factors, thereby blocking their transactivational activity (41) . Hey-1 also was able to efficiently repress AR transcriptional activity by binding to the AF1 domain of the receptor (42) . These findings are significant because GATA-2 and GATA-3 transcription factors in concert with AR regulate prostate epithelial differentiation (9, 43) . In particular, PSA enhancer, in addition to numerous AR-binding sites, also contains six GATA-binding sites, which are essential for proper AR-regulated transactivation of PSA (43 To elucidate whether such lack of differentiation is due to continuous Notch-1/Hey-1 signaling, we evaluated expression of these markers and GATA-2 transcription factor in these lines. Western blot analysis documents that Notch-1/Hey-1 signaling is active in all of the studied normal epithelial lines because both the cleaved 110-kDa Notch-1 fragment and its downstream effector Hey-1 are expressed. Interestingly, none of the studied normal prostate lines expressed GATA-2 protein, which is consistent with the ability of Hey-1 to repress expression of GATA-2 and subsequent differentiation. As documented in Fig. 5D 
Discussion
The present studies characterized the origin and cellular composition of normal nonimmortalized human PrEC prostate Research. Understanding the cell of origin and composition of the available primary and immortalized prostate cell lines is critical for studying the processes of normal epithelial differentiation and prostatic carcinogenesis. Identification of the cell of origin for prostate carcinogenesis is presently unresolved. A critical question that requires our attention is whether this initiating prostate cancer cell is a transformed genetically unstable stem cell or whether it is one of its more differentiated progeny (45) (46) (47) . A growing body of evidence suggests that, once initiated, such a genetically unstable cell behaves as a ''cancer stem cell'' (47) . The defining characteristic of such a ''cancer stem cell'' is its retention of unlimited self-renewal while allowing a subset of its progeny to mature down an aberrant differentiation/maturation pathway toward the luminal-secretory cell phenotype. Coupled with such an aberrant maturation process, these more differentiated malignant progeny retain only a limited ability to proliferate. Thus, under this scenario, the continuous malignant growth (i.e., clonal expansion) is maintained by the proliferation of cancer stem cells and not the progeny that undergo limited proliferation before terminally differentiating. Theoretically, such ''cancer stem cells'' can be derived as a result of transformation of an undifferentiated normal stem cell and/or from any of its more differentiated progeny (i.e., neuroendocrine, transit-amplifying, intermediate, and secretory cells). Effective therapy must eradicate malignant cells with unlimited clonogenic expansion ability (i.e., cancer stem cells) within the cancer population regardless of whether such cancer stem cells are derived from undifferentiated normal stem cells or its more differentiated progeny.
Resolving the specific cell of origin for prostate cancer is critical to appropriately define rational targets for therapeutic intervention, because there are major differences in the growth-regulatory pathways for stem cells versus their more differentiated progeny (48) . For example, the targeting of AR axis is the most obvious point in question. In prostatic cancer, there are molecular changes that convert the AR axis from a tumor suppressor of normal prostatic epithelial growth to a gain of function tumor oncogene directly stimulating prostate cancer cell growth (9) . If prostate cancer stem cells are derived from transformed normal stem cells in which AR is not expressed, then such androgen stimulation occurs via enhancing the growth not of the cancer stem cells but of their AR + differentiated progeny. In such circumstances, androgen ablation would inhibit growth of these more differentiated progeny but not of the cancer stem cells and thus would not be curative no matter how complete is the extent of ablation (48) . This would explain why current standard of care ''complete androgen ablation'' has failed to be curative against prostate cancer (49) .
Recently, additional evidence suggesting that cancer stem cells are androgen and AR independent was put forth by Collins et À growing cancers when xenografted into nude mice. In summary, the current study provides critical knowledge on the cellular origin and biological heterogeneity due to in vitro differentiation of several available prostate epithelial cell lines and documents that low Ca 2+ SFD medium selects for growth of normal prostate epithelial stem and transit-amplifying cells. Such knowledge should enable and facilitate the studying of prostate epithelial differentiation and prostatic carcinogenesis.
